Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation Safety and Efficacy Study of NP001in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic ...
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001in Subjects With A ...
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001in Subjects With A ...
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Single-Ascending-Dose Safety and Tolerability Study of NP001in Subjects With Amyotrophic Lateral Scl ...